As the occurrence of BMs continues to increase in breast cancer patients (4,5), some reports propose clinical trials focusing on the value of BM screening in patients with breast cancer, particularly for subgroups at high risk of BMs (i.e., HER2 or TNBC with extracranial metastatic lesions) (28). Here, ERBB2 is linked to breast carcinoma.